title: Antiandrogenic therapy can cause coronary arterial disease.
abstract: OBJECTIVE
  To study the change of lipid metabolism by antiandrogen therapy in patients with prostate cancer.
  
  
  METHODS
  We studied with a 2.5 years follow-up the changes in plasma cholesterols (C), triglycerides (TG), lipoproteins (LP), and apolipoproteins (Apo) B-100, A-I, and A-II pro fi les in 24 patients of mean age 60 years with low risk prostate cancer (stage: T1cN0M0, Gleason score: 2-5) during treatment with cyproterone acetate (CPA) without surgical management or radiation therapy.
  
  
  RESULTS
  Significant decreases of HDL-C, Apo A-I and Apo A-II and an increase of triglyceride levels in VLDL were induced by CPA. After a period of 2.5 years on CPA treatment, four patients out of twenty-four were found to be affected by coronary heart disease.
  
  
  CONCLUSIONS
  Ischaemic coronary arteriosclerosis with an incidence rate of 16.6% as caused by prolonged CPA therapy is mediated through changes in HDL cholesterol, Apo A-I and Apo A-II pro fi les, other than the well-known hyperglyceridemic effect caused by estrogen.
authors.affiliation: Graduate Institute of Medical Science, Taipei Medical University, Taiwan, China.
authors.forename: Kuan-Chou
authors.initials: KC
authors.lastname: Chen
authors.forename: Chiung-Chi
authors.initials: CC
authors.lastname: Peng
authors.forename: Hsiu-Mei
authors.initials: HM
authors.lastname: Hsieh
authors.forename: Chiung-Huei
authors.initials: CH
authors.lastname: Peng
authors.forename: Chiu-Lan
authors.initials: CL
authors.lastname: Hsieh
authors.forename: Chien-Ning
authors.initials: CN
authors.lastname: Huang
authors.forename: Charng-Cherng
authors.initials: CC
authors.lastname: Chyau
authors.forename: Hui-Er
authors.initials: HE
authors.lastname: Wang
authors.forename: Robert Y
authors.initials: RY
authors.lastname: Peng
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D016632:Apolipoprotein A-I / Q000097:blood; D016633:Apolipoprotein A-II / Q000097:blood; D015415:Biomarkers / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D003327:Coronary Disease / Q000097:blood / Q000139:chemically induced* / Q000503:physiopathology; D017373:Cyproterone Acetate / Q000009:adverse effects* / Q000627:therapeutic use; D004562:Electrocardiography; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D012307:Risk Factors; D014280:Triglycerides / Q000097:blood
chemical_list: D000726:Androgen Antagonists; D016632:Apolipoprotein A-I; D016633:Apolipoprotein A-II; D015415:Biomarkers; D008076:Cholesterol, HDL; D014280:Triglycerides; D017373:Cyproterone Acetate